Agios Pharmaceuticals (NASDAQ: AGIO) revenue
Agios Pharmaceuticals reported revenue of $54.0m for fiscal 2025, 48.0% more than in fiscal 2024 ($36.5m). Since fiscal 2016 its revenue has fallen by 22.7%, an average decline of 2.8% a year.
Agios Pharmaceuticals has grown its revenue for 3 years in a row, and its best year of the last 10 was fiscal 2019. The biggest drop was in fiscal 2017, −38.5%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $54.0m | +48.0% | −$472.1m | −873.9% |
| 2024 | $36.5m | +36.1% | −$425.7m | −1,166.5% |
| 2023 | $26.8m | +88.4% | −$391.5m | −1,459.5% |
| 2022 | $14.2m | — | −$389.0m | −2,732.1% |
| 2021 | $0.0m | — | −$378.4m | — |
| 2020 | $0.0m | −100.0% | −$335.9m | — |
| 2019 | $117.9m | +24.9% | −$316.3m | −268.2% |
| 2018 | $94.4m | +119.4% | −$362.5m | −384.0% |
| 2017 | $43.0m | −38.5% | −$320.8m | −745.8% |
| 2016 | $69.9m | — | −$201.0m | −287.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Agios Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Agios Pharmaceuticals ranks 324th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Agios Pharmaceuticals, 48.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 322nd | 908 Devices | $56.2m | 17.7% |
| 323rd | Nektar Therapeutics | $55.2m | −43.9% |
| 324th | Agios Pharmaceuticals | $54.0m | 48.0% |
| 325th | Invivyd | $53.4m | 110.5% |
| 326th | Protalix Biotherapeutics | $52.7m | −1.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Agios Pharmaceuticals
- How much revenue did Agios Pharmaceuticals make in fiscal 2025?
- Agios Pharmaceuticals reported revenue of $54.0m for fiscal 2025, compared with $36.5m in fiscal 2024.
- How much has the revenue of Agios Pharmaceuticals fallen?
- Between fiscal 2016 and fiscal 2025 it went from $69.9m to $54.0m: 22.7% less, an average decline of 2.8% a year.
- What was the best year for revenue at Agios Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2019, with $117.9m.
- Where does Agios Pharmaceuticals rank in its sector by revenue?
- It ranks 324th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Agios Pharmaceuticals come from?
- From the annual report (Form 10-K) that Agios Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Agios Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Agios Pharmaceuticals: the Agios Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.